Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, Eshagh D, Adotevi O, Laheurte C, Ricard L, Dulery R, Stocker N, van de Wyngaert Z, Genthon A, Banet A, Memoli M, Ikhlef S, Sestilli S, Vekhof A, Brissot E, Marjanovic Z, Chantran Y, Cuervo N, Ballot E, Morand-Joubert L, Mohty M. Malard F, et al. Among authors: adotevi o. Blood Cancer J. 2021 Aug 10;11(8):142. doi: 10.1038/s41408-021-00534-z. Blood Cancer J. 2021. PMID: 34376633 Free PMC article.
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O. Godet Y, et al. Among authors: adotevi o. Clin Cancer Res. 2012 May 15;18(10):2943-53. doi: 10.1158/1078-0432.CCR-11-3185. Epub 2012 Mar 8. Clin Cancer Res. 2012. PMID: 22407833 Free article.
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O. Beziaud L, et al. Among authors: adotevi o. Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17. Cancer Res. 2016. PMID: 27197194
Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.
Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O. Laheurte C, et al. Among authors: adotevi o. Oncoimmunology. 2016 Feb 18;5(5):e1137416. doi: 10.1080/2162402X.2015.1137416. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467955 Free PMC article.
Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.
Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O. Picard E, et al. Among authors: adotevi o. Oncoimmunology. 2018 Oct 19;8(2):e1527498. doi: 10.1080/2162402X.2018.1527498. eCollection 2019. Oncoimmunology. 2018. PMID: 30713781 Free PMC article.
Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.
Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O. Laheurte C, et al. Among authors: adotevi o. Br J Cancer. 2019 Aug;121(5):405-416. doi: 10.1038/s41416-019-0531-5. Epub 2019 Jul 30. Br J Cancer. 2019. PMID: 31358938 Free PMC article.
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y. Galaine J, et al. Among authors: adotevi o. Int J Cancer. 2019 Dec 1;145(11):3112-3125. doi: 10.1002/ijc.32620. Epub 2019 Aug 31. Int J Cancer. 2019. PMID: 31396953 Free article.
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard S, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P. Teixeira L, et al. Among authors: adotevi o. Clin Cancer Res. 2020 Feb 1;26(3):588-597. doi: 10.1158/1078-0432.CCR-19-1614. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558479
Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O. Laheurte C, et al. Among authors: adotevi o. Int J Cancer. 2020 Aug 15;147(4):1199-1205. doi: 10.1002/ijc.32803. Epub 2019 Dec 11. Int J Cancer. 2020. PMID: 31749145 Free article.
109 results